Free Trial

DBV Technologies (DBVT) Competitors

DBV Technologies logo
$14.86 -0.26 (-1.72%)
Closing price 04:00 PM Eastern
Extended Trading
$14.91 +0.05 (+0.34%)
As of 06:20 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

DBVT vs. IMCR, VCEL, JANX, EWTX, RCUS, HRMY, AUPH, PAHC, SDGR, and HROW

Should you be buying DBV Technologies stock or one of its competitors? The main competitors of DBV Technologies include Immunocore (IMCR), Vericel (VCEL), Janux Therapeutics (JANX), Edgewise Therapeutics (EWTX), Arcus Biosciences (RCUS), Harmony Biosciences (HRMY), Aurinia Pharmaceuticals (AUPH), Phibro Animal Health (PAHC), Schrodinger (SDGR), and Harrow (HROW). These companies are all part of the "pharmaceutical products" industry.

DBV Technologies vs. Its Competitors

DBV Technologies (NASDAQ:DBVT) and Immunocore (NASDAQ:IMCR) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, earnings, analyst recommendations, valuation, media sentiment, profitability and risk.

Immunocore has higher revenue and earnings than DBV Technologies. Immunocore is trading at a lower price-to-earnings ratio than DBV Technologies, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
DBV Technologies$4.15M98.11-$113.92M-$4.77-3.12
Immunocore$310.20M5.13-$51.09M-$0.40-79.00

Immunocore has a net margin of -5.70% compared to DBV Technologies' net margin of -3,220.49%. Immunocore's return on equity of -5.40% beat DBV Technologies' return on equity.

Company Net Margins Return on Equity Return on Assets
DBV Technologies-3,220.49% -287.15% -138.83%
Immunocore -5.70%-5.40%-1.93%

DBV Technologies has a beta of -0.45, suggesting that its stock price is 145% less volatile than the S&P 500. Comparatively, Immunocore has a beta of 0.79, suggesting that its stock price is 21% less volatile than the S&P 500.

In the previous week, Immunocore had 5 more articles in the media than DBV Technologies. MarketBeat recorded 5 mentions for Immunocore and 0 mentions for DBV Technologies. DBV Technologies' average media sentiment score of 1.00 beat Immunocore's score of 0.46 indicating that DBV Technologies is being referred to more favorably in the media.

Company Overall Sentiment
DBV Technologies Positive
Immunocore Neutral

71.7% of DBV Technologies shares are held by institutional investors. Comparatively, 84.5% of Immunocore shares are held by institutional investors. 1.4% of DBV Technologies shares are held by insiders. Comparatively, 10.4% of Immunocore shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

DBV Technologies currently has a consensus price target of $14.75, indicating a potential downside of 0.74%. Immunocore has a consensus price target of $56.89, indicating a potential upside of 80.03%. Given Immunocore's higher possible upside, analysts plainly believe Immunocore is more favorable than DBV Technologies.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
DBV Technologies
2 Sell rating(s)
1 Hold rating(s)
3 Buy rating(s)
1 Strong Buy rating(s)
2.43
Immunocore
2 Sell rating(s)
4 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.33

Summary

Immunocore beats DBV Technologies on 12 of the 17 factors compared between the two stocks.

Get DBV Technologies News Delivered to You Automatically

Sign up to receive the latest news and ratings for DBVT and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding DBVT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

DBVT vs. The Competition

MetricDBV TechnologiesMED IndustryMedical SectorNASDAQ Exchange
Market Cap$414.21M$3.44B$6.19B$10.60B
Dividend YieldN/A2.26%5.72%4.86%
P/E Ratio-3.1223.2429.6428.46
Price / Sales98.11477.59577.46128.87
Price / CashN/A44.5736.5560.64
Price / Book10.4610.3512.076.53
Net Income-$113.92M-$52.53M$3.32B$276.75M
7 Day Performance-12.59%-0.22%-0.16%0.20%
1 Month Performance58.93%10.89%5.76%1.67%
1 Year Performance336.99%14.19%65.71%32.73%

DBV Technologies Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
DBVT
DBV Technologies
1.3024 of 5 stars
$14.86
-1.7%
$14.75
-0.7%
+332.0%$414.21M$4.15M-3.1280Positive News
IMCR
Immunocore
2.6591 of 5 stars
$32.35
-0.2%
$56.89
+75.9%
-2.4%$1.63B$310.20M-80.88320News Coverage
Analyst Forecast
VCEL
Vericel
3.4108 of 5 stars
$33.49
+5.1%
$60.40
+80.4%
-12.9%$1.61B$237.22M279.11300
JANX
Janux Therapeutics
2.0635 of 5 stars
$26.29
-0.8%
$78.31
+197.9%
-50.1%$1.59B$10.59M-14.6130News Coverage
EWTX
Edgewise Therapeutics
3.2576 of 5 stars
$14.71
-2.6%
$38.83
+164.0%
-56.7%$1.59BN/A-9.4960
RCUS
Arcus Biosciences
2.5953 of 5 stars
$16.64
+14.0%
$26.78
+61.0%
-0.6%$1.55B$258M-5.25500Analyst Forecast
HRMY
Harmony Biosciences
4.8023 of 5 stars
$26.36
-0.7%
$46.11
+74.9%
-24.6%$1.53B$714.73M8.50200Positive News
AUPH
Aurinia Pharmaceuticals
2.7801 of 5 stars
$11.10
-1.5%
$13.00
+17.1%
+67.2%$1.48B$235.13M25.81300Positive News
PAHC
Phibro Animal Health
3.8448 of 5 stars
$36.58
+0.5%
$28.40
-22.4%
+66.2%$1.48B$1.30B31.002,475Insider Trade
SDGR
Schrodinger
3.5342 of 5 stars
$19.70
+3.2%
$26.29
+33.4%
+11.3%$1.40B$207.54M-7.94790News Coverage
HROW
Harrow
2.941 of 5 stars
$38.77
+3.4%
$68.50
+76.7%
-31.7%$1.39B$199.61M-155.08180

Related Companies and Tools


This page (NASDAQ:DBVT) was last updated on 10/23/2025 by MarketBeat.com Staff
From Our Partners